Navigation Links
Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
Date:9/21/2010

nitial registration statement, Anthera has agreed to file subsequent registration statements until all the shares have been registered, and the registration rights agreement imposes certain customary cash penalties on Anthera for its failure to satisfy specified filing and effectiveness time periods.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2 . Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (or BAFF, or BLyS), which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include statements relating to whether and when the private placement will close, Anthera's anticipated uses of the net proceeds of the transaction and whether and when Anthera's Board of Directors will appoint Dr. Peter Thompson to Anthera's Board of Directors. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cau
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
2. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
3. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
4. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
5. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
6. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
7. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
11. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015 The Coalition of State ... and regional professional rheumatology societies, today released the ... explored perceptions of biosimilars and the potential impact ... Biosimilars are medicines that are highly similar, ... notably different from generic medications in that it ...
(Date:7/1/2015)... INDIANAPOLIS , July 1, 2015 Eli Lilly ... results for the second quarter of 2015 on Thursday, July ... that day with the investment community and media to further ... will begin at 9 a.m. EDT. Investors, media and the ... call through a link that will be posted on Lilly,s ...
(Date:7/1/2015)... According to a new market research report ... Synthetic, Fibrin, Collagen, Gelatin, Cyanoacrylate, Polymeric, Polyurethane), by Application ... 2020", published by MarketsandMarkets, the global Surgical Sealants and ... 2020, growing at a CAGR of 9.2% during the ... 119 market T ables and 29 ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 2Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 3Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 4
... MONTRÉAL, June 1, 2007 – Thallion Pharmaceuticals Inc.,(TSX: ... Phase,I/II clinical trial investigating ECO-4601 in advanced cancer,patients ... the American,Society of Clinical Oncology (ASCO) Annual Meeting ... portion of the study, 14,patients (ten colorectal, two ...
... -- Data Presented at Annual Meeting of the ... Calif. -- June 4, 2007 -- SciClone Pharmaceuticals,Inc. ... product candidate thymalfasin (ZADAXIN(r), thymosin,alpha 1) achieved its ... patients diagnosed with stage IV malignant melanoma, the,most ...
Cached Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3
(Date:7/2/2015)... ... July 02, 2015 , ... ... providers, has been retained to lead a national chief operating officer recruitment ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... overall status of the Gelatin Capsule manufacturers. The report is a valuable source ... The report depicts the global and Chinese market for the Gelatin Capsule industry ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... solutions for drugs, biologics and consumer health products, today announced that it has ... Irmgard Neuper is the new General Manager at Catalent’s Schorndorf facility, which provides ...
(Date:7/2/2015)... ... July 02, 2015 , ... Today, East Liverpool City Hospital ... Center at East Liverpool City Hospital (ELCH). Pam is currently the Chief Nursing Officer ... director of surgery. Pam holds a master’s degree in health care administration as well ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... Garramone introduced CoolSculpting Plus, an advanced approach to body contouring. CoolSculpting ... to 44%. , About the basic CoolSculpting procedure:, The CoolSculpting procedure ...
Breaking Medicine News(10 mins):Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 2Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 3Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 4
... the Democrats, supermajority necessary to pass comprehensive national ... promote greater efficiency in the medical delivery system. ... accelerate delivery system change but would be highly ... proposals that provide new authority for the Centers ...
... ... ... ... ...
... ... ... ... ...
... heart disease most susceptible to potential problems, small study suggests ... raise the risk for experiencing heartbeat irregularities among older individuals ... , The finding stems from an assessment of a small ... of heart disease -- who were observed in an environment ...
... ... lawyer, David Perecman, questions whether anyone should continue driving them before having them fixed. , ... New York (PRWEB) March 4, 2010 -- In ... New York Post , Jerry Silver, 86, lost control of his car and collided with ...
... warmer than 75 degrees poses added risks , THURSDAY, March ... deaths in New York City go up with the temperature: ... 75 degrees Fahrenheit. , The findings, published online March ... death statistics in the city from 1990 through 2006. , ...
Cached Medicine News:Health News:Experts support new federal center for Medicare and Medicaid innovation 2Health News:SarahCare(R) and Posit Science Corporation(R) Join Forces to Bring Brain Fitness to Seniors at SarahCare(R) of Minnesota 2Health News:SarahCare(R) and Posit Science Corporation(R) Join Forces to Bring Brain Fitness to Seniors at SarahCare(R) of Minnesota 3Health News:SarahCare(R) and Posit Science Corporation(R) Join Forces to Bring Brain Fitness to Seniors at SarahCare(R) of Minnesota 4Health News:SarahCare(R) and Posit Science Corporation(R) Join Forces to Bring Brain Fitness to Seniors at SarahCare(R) of Minnesota 5Health News:National Healthcare Leaders in San Francisco to Address Health Reform and Payment Reform 2Health News:National Healthcare Leaders in San Francisco to Address Health Reform and Payment Reform 3Health News:National Healthcare Leaders in San Francisco to Address Health Reform and Payment Reform 4Health News:Air Travel Could Raise Risk for Heartbeat Irregularities 2Health News:Air Travel Could Raise Risk for Heartbeat Irregularities 3Health News:New York Personal Injury Lawyers Concerned About Toyota Accident in Queens 2Health News:New York Personal Injury Lawyers Concerned About Toyota Accident in Queens 3
... Fibrin Sealant has been shown to be ... Containing uniform, reproducible concentrations of fibrinogen and ... final stage of the coagulation cascade to ... firmly adheres to connective tissue like a ...
... catheter is inserted into the subclavian or ... vena cava. The Cool Line incorporates ... temperature-controlled saline flowing within a closed-loop design, ... circulation. The Cool Line combines two ...
... The Fortius catheter provides maximum ... to target temperature. The Fortius catheter ... design to provide the ultimate solution ... catheter is inserted percutaneously into the ...
...
Medicine Products: